Prostate Volume Calculator

Accurate prostate volume estimation using the standard ellipsoid method (L × W × H × π/6). Calculate PSA density (PSAD), interpret volume thresholds for benign prostatic hyperplasia (BPH) and prostate cancer risk assessment.

Cranio-caudal or anteroposterior dimension
Left to right diameter
Superoinferior dimension
Serum prostate-specific antigen, for PSAD calculation
All measurements in centimeters (1 cm = 10 mm) — volume = cm³ = mL
? Normal adult (35 y): L=3.5, W=4.0, H=3.2, PSA=1.2
? Moderate BPH: L=4.5, W=5.2, H=4.3, PSA=3.8
? Severe enlargement: L=6.0, W=6.5, H=5.5, PSA=7.2
⚠️ Elevated PSAD: L=4.0, W=4.5, H=4.0, PSA=6.5
Private & local: All calculations run in your browser. No medical data stored or transmitted.
Clinical disclaimer: This tool provides estimates based on the ellipsoid formula (standard in transrectal ultrasound). Results are for educational and research use only; always confirm with specialist evaluation and imaging.

Clinical significance & formula accuracy

The prostate volume calculator employs the validated ellipsoid volume formula (L × W × H × π/6). This method is endorsed by the European Association of Urology (EAU) and the American Urological Association (AUA) for transrectal ultrasonography (TRUS) and MRI-based volumetry. Accurate volume assessment guides decisions for benign prostatic hyperplasia (BPH) therapy, prostate biopsy strategies, and active surveillance in prostate cancer.

Ellipsoid Volume (cm³) = (Length × Width × Height) × (π/6) ≈ (L × W × H) × 0.5236

PSA Density (PSAD) = serum PSA (ng/mL) / prostate volume (cm³)

PSA density refines prostate cancer risk prediction: levels >0.15 ng/mL/cm³ are associated with higher malignancy probability, while thresholds >0.20 increase suspicion regardless of total PSA. Our tool integrates volume and PSAD to support evidence-based clinical reasoning.

Reference ranges & clinical thresholds

Prostate volume (cm³) Interpretation Clinical context
15 – 25 Normal (young adult) Typical for ages 20-40, low BPH probability
25 – 40 Mild enlargement Early BPH; consider watchful waiting or medical therapy
40 – 70 Moderate hypertrophy Symptomatic BPH, possible surgical evaluation
> 70 Severe enlargement High risk of acute retention; often requires intervention (TURP, HoLEP)

PSA Density risk stratification

  • PSAD ≤ 0.10 : Low suspicion for clinically significant cancer (if PSA moderately elevated, consider other causes).
  • PSAD 0.10 – 0.15 : Intermediate zone; use additional biomarkers or MRI.
  • PSAD 0.15 – 0.20 : Elevated risk; discuss biopsy in appropriate candidates.
  • PSAD > 0.20 : High probability of prostate cancer; urological referral strongly advised.
Case study: different management pathways

Patient A: 62 y/o with PSA 4.2 ng/mL, volume 48 cm³ → PSAD = 0.087. Interpretation: BPH-related elevation, low cancer suspicion. Recommended: repeat PSA in 6 months, alpha-blocker trial.
Patient B: 58 y/o, PSA 5.8 ng/mL, volume 31 cm³ → PSAD = 0.187. The threshold >0.15 suggests increased malignancy risk; MRI fusion biopsy detected Gleason 7 cancer. Volume calculator directly changed clinical strategy.

Based on data from Roobol et al. (European Urology, 2021) and AUA Guidelines for Early Detection of Prostate Cancer.

Why measure prostate volume routinely?

Volume quantification helps predict progression of lower urinary tract symptoms (LUTS), risk of acute urinary retention, and response to 5-alpha-reductase inhibitors. It also assists in calculating PSA density which outperforms total PSA alone. The ellipsoid formula demonstrates correlation coefficients >0.9 compared to planimetric or 3D segmentation on MRI (Turkbey et al., Radiology 2019).

Methodological validation & references

  • Ellipsoid approximation error ≤10% relative to true prostatic volume in most shape variations.
  • IUGA/ICS recommend standardized reporting of three diameters (AP, transverse, CC).
  • Source: Campbell-Walsh-Wein Urology, 12th Edition; EAU Guidelines on Prostate Cancer (2025).

Step-by-step calculation logic

  1. Capture three linear measurements (cm) from ultrasound/MRI: length (anteroposterior), width (transverse), height (craniocaudal).
  2. Compute ellipsoid volume = (L × W × H) × (π/6).
  3. If PSA value provided, calculate PSAD = PSA / volume (ng/mL/cm³).
  4. Compare volume and PSAD against evidence-based reference intervals.

Frequently Asked Questions (FAQs)

Yes. Both imaging modalities allow linear measurements; the ellipsoid formula is the standard clinical surrogate for prostate volume. However, 3D segmentation on MRI is more precise, but our calculator serves rapid estimation.

The ellipsoid method requires all three dimensions for accurate volumetric estimation. Using an assumed value might cause error; we recommend consulting your imaging report.

PSA density improves with age-specific reference but the threshold of 0.15 ng/mL/cm³ is widely applicable for biopsy decision. Adjustments may apply in very large glands (>70 cm³) where density might be artificially lowered.

Studies show excellent correlation (r=0.93) between ellipsoid volume and actual weight of radical prostatectomy specimens. Underestimation may occur in irregular shapes but remains clinically acceptable.

Convert millimeters to centimeters by dividing by 10. The calculator expects cm; using mm directly would yield volume 1000x larger (invalid).

Developed in cooperation with clinical urology experts — This tool references peer-reviewed guidelines (EAU, AUA, NCCN) and is periodically reviewed by getzenquery tech team. Updated June 2026. The ellipsoid implementation follows the mathematical derivation from Weisstein, Eric W. "Ellipsoid." MathWorld and clinical volumetry standards.

Literature: AUA Early Detection Guideline | EAU Prostate Cancer Guidelines | Roehrborn CG, J Urol 2001;165(5):1496-500.